Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
Trump accepts Nobel medal from Venezuelan opposition leader Machado
At least seven killed in Uganda violence, Museveni dominates election results
Thailand halts multiple major construction projects after fatal accidents
Bus crashes into building in South Korea, leaving 13 injured, Yonhap says
South Korea's ex-president Yoon given 5-year jail term in first ruling over martial law
